IL307794A - Treatment of eye diseases using endothelin receptor antagonists - Google Patents
Treatment of eye diseases using endothelin receptor antagonistsInfo
- Publication number
- IL307794A IL307794A IL307794A IL30779423A IL307794A IL 307794 A IL307794 A IL 307794A IL 307794 A IL307794 A IL 307794A IL 30779423 A IL30779423 A IL 30779423A IL 307794 A IL307794 A IL 307794A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- receptor antagonists
- endothelin receptor
- ocular diseases
- ocular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182750P | 2021-04-30 | 2021-04-30 | |
| PCT/US2022/027045 WO2022232586A1 (en) | 2021-04-30 | 2022-04-29 | Treatment of ocular diseases using endothelin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307794A true IL307794A (en) | 2023-12-01 |
Family
ID=83848733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307794A IL307794A (en) | 2021-04-30 | 2022-04-29 | Treatment of eye diseases using endothelin receptor antagonists |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240058265A1 (https=) |
| EP (1) | EP4329810A4 (https=) |
| JP (1) | JP2024516829A (https=) |
| CN (1) | CN117295520A (https=) |
| AU (1) | AU2022264438A1 (https=) |
| CA (1) | CA3218398A1 (https=) |
| IL (1) | IL307794A (https=) |
| MX (1) | MX2023012826A (https=) |
| WO (1) | WO2022232586A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4329753A4 (en) * | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049630A2 (en) * | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| BRPI1013904A2 (pt) * | 2009-04-30 | 2016-07-19 | Univ Midwestern | método e composição para tratar cetoacidose diabética |
| US20120087864A1 (en) * | 2010-04-12 | 2012-04-12 | R-Tech Ueno, Ltd. | Method for diagnosing and/or evaluating retinal disease |
| CA2949954A1 (en) * | 2014-05-23 | 2015-11-26 | Ocular Technologies Sarl | Topical formulations and uses thereof |
| WO2018185516A1 (en) * | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| JP2020528082A (ja) * | 2017-07-17 | 2020-09-17 | ロイズマン,キース | 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 |
| EP4050997A4 (en) * | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
| CA3168810A1 (en) * | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| EP4329753A4 (en) * | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
-
2022
- 2022-04-29 CA CA3218398A patent/CA3218398A1/en active Pending
- 2022-04-29 CN CN202280032071.2A patent/CN117295520A/zh active Pending
- 2022-04-29 WO PCT/US2022/027045 patent/WO2022232586A1/en not_active Ceased
- 2022-04-29 EP EP22796855.9A patent/EP4329810A4/en active Pending
- 2022-04-29 MX MX2023012826A patent/MX2023012826A/es unknown
- 2022-04-29 JP JP2023566519A patent/JP2024516829A/ja active Pending
- 2022-04-29 IL IL307794A patent/IL307794A/en unknown
- 2022-04-29 AU AU2022264438A patent/AU2022264438A1/en active Pending
-
2023
- 2023-10-25 US US18/494,545 patent/US20240058265A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012826A (es) | 2023-11-13 |
| US20240058265A1 (en) | 2024-02-22 |
| WO2022232586A1 (en) | 2022-11-03 |
| EP4329810A4 (en) | 2025-02-26 |
| EP4329810A1 (en) | 2024-03-06 |
| CN117295520A (zh) | 2023-12-26 |
| CA3218398A1 (en) | 2022-11-03 |
| JP2024516829A (ja) | 2024-04-17 |
| AU2022264438A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276383B1 (en) | Treatment of ophthalmological diseases | |
| IL289405A (en) | Personalized treatment of eye diseases | |
| EP4050997A4 (en) | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | |
| IL278178A (en) | Use of pilocarpine hydrochloride to treat eye disorder | |
| IL291665A (en) | Inhibitors of receptor interaction with protein kinase i for the treatment of disease | |
| HUE067909T2 (hu) | Pirimidin JAK-inhibitorok bõrbetegségek kezelésére | |
| BR112017024852A2 (pt) | antagonistas de receptor nk-1/nk-3 duplo para o tratamento de doenças dependentes de hormônio sexual | |
| IL287802A (en) | Preparations and methods for the treatment of eye diseases | |
| IL268357A (en) | Photoreceptor cells for the treatment of retinal diseases | |
| EP3271015B8 (en) | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | |
| SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| PT3603621T (pt) | Lipossomas para o tratamento de doenças oculares | |
| IL282361A (en) | Treatment for neurological diseases | |
| SG11202001595SA (en) | Angio-3 for treatment of retinal angiogenic diseases | |
| IL307794A (en) | Treatment of eye diseases using endothelin receptor antagonists | |
| IL291439A (en) | Methods for treating autoimmune diseases using interleukin-17 (il-17) antagonists | |
| ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
| SG11202010034WA (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY | |
| IL306009A (en) | Ocular transfer of therapeutic agents | |
| HK40107454A (en) | Treatment of ocular diseases using endothelin receptor antagonists | |
| IL299383A (en) | Use of N-phenylacetamides with P2X4 receptor antagonist activity to treat certain eye disorders | |
| HK40080625A (en) | Treatment of ocular diseases using endothelin receptor antagonists | |
| IL255796A0 (en) | Manual implantation devices for transplanting a retinal tissue graft | |
| IL290079A (en) | Use of very strong multimeric antagonists for selectin-e for the treatment of sickle cell anemia |